Application of the CIBMTR risk score to patients with systemically treated NIH chronic GVHD between 2006 and 2010 at 2 individual centers. Data represented includes (A) proportions of risk groups, (B) overall survival, and (C) non-relapse mortality. Diseases included acute myeloid leukemia (n = 215), acute lymphoblastic leukemia (n = 63), chronic myeloid leukemia (n = 28), and myelodysplastic syndrome (n = 70). Ages were ≤29 years in 54 patients (14%), 30 to 59 years in 237 patients (63%), and ≥60 years in 85 patients (23%); 279 patients (74%) had prior acute GVHD. Time from transplantation to chronic GVHD was <5 months in 124 patients (33%). Hyperbilirubinemia and thrombocytopenia were present in 17 (5%) and 109 (29%) patients, respectively, at the onset of systemic treatment. Karnofsky score was <80% in 117 patients (31%). Donor was a HLA identical sibling in 160 patients (43%), an HLA well-matched or partially matched unrelated donor in 171 patients (45%), and other related or HLA mismatched unrelated donor in 45 patients (12%). Disease status at transplantation was early in 225 patients (60%), intermediate in 84 patients (22%), and advanced in 67 patients (18%). Ninety-one male patients (24%) had transplantation from a female donor. GVHD prophylaxis was cyclosporine based in 146 patients (39%) and tacrolimus based or T-cell depletion in 230 patients (61%). Karnofsky score ≥80%, HLA identical sibling donor, early disease, and cyclosporine-based GVHD prophylaxis were more frequent at PMH than at FHCRC, and other characteristics were similar between the 2 centers. Curves for risk scores >3 are not shown due to a small numbers of patients.